retatrutide alternative Safety, Side Effects & Provider Use With retatrutide approaching ~30% weight

Retatrutide (GLP-3) is a next-generation triple receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously

The clinical significance of this effect is not fully characterized, but some providers recommend that women on oral contraceptives switch to a non-oral method (patch, ring, IUD, implant) when starting GLP-1 therapy, or use backup contraception during the titration period

Neither tirzepatide nor semaglutide has demonstrated liver fat reductions approaching the 80%+ figures seen with retatrutide

Notable interactions include: Diuretics (furosemide, spironolactone) Insulin or insulin secretagogues (sulfonylureas) Lithium Alcohol Recommended dose Start with 10 mg once daily in the morning, with or without food